NERMIN ALY: Open Payments
NPI 1184486193 · NEW BRUNSWICK, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$226 in 12 payments from 11 companies in 2025. Trend: 2023 $0 · 2024 $301 · 2025 $226
Food & beverage: $226
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 2 | $36 |
| Lilly USA, LLC | 1 | $22 |
| PFIZER INC. | 1 | $22 |
| SpringWorks Therapeutics, Inc. | 1 | $20 |
| Neurocrine BioSciences, Inc. | 1 | $20 |
| Novartis Pharmaceuticals Corporation | 1 | $20 |
| AstraZeneca Pharmaceuticals LP | 1 | $19 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $18 |
| ACADIA Pharmaceuticals Inc | 1 | $17 |
| UCB, Inc. | 1 | $16 |
Products named: PONVORY, KISUNLA, GOMEKLI, INGREZZA, KESIMPTA, Kerendia, NUPLAZID, Nayzilam.
Industry payments across NJ — which companies pay providers there.
